Coldstream Capital Management Inc. Has $4.44 Million Position in Stryker Corporation $SYK

Coldstream Capital Management Inc. lifted its stake in shares of Stryker Corporation (NYSE:SYK) by 23.0% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 12,007 shares of the medical technology company’s stock after purchasing an additional 2,248 shares during the quarter. Coldstream Capital Management Inc.’s holdings in Stryker were worth $4,440,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also added to or reduced their stakes in the company. Vanguard Group Inc. boosted its position in Stryker by 0.8% in the third quarter. Vanguard Group Inc. now owns 33,773,399 shares of the medical technology company’s stock valued at $12,485,012,000 after buying an additional 272,828 shares in the last quarter. State Street Corp grew its stake in shares of Stryker by 1.0% during the second quarter. State Street Corp now owns 14,956,732 shares of the medical technology company’s stock worth $5,929,765,000 after buying an additional 150,204 shares during the last quarter. Alliancebernstein L.P. increased its holdings in shares of Stryker by 13.3% during the third quarter. Alliancebernstein L.P. now owns 6,338,050 shares of the medical technology company’s stock worth $2,342,987,000 after buying an additional 741,542 shares in the last quarter. Norges Bank bought a new position in shares of Stryker in the 2nd quarter valued at $1,882,173,000. Finally, Legal & General Group Plc lifted its stake in shares of Stryker by 4.4% in the 3rd quarter. Legal & General Group Plc now owns 2,303,290 shares of the medical technology company’s stock valued at $851,457,000 after acquiring an additional 96,662 shares during the last quarter. 77.09% of the stock is currently owned by institutional investors and hedge funds.

Stryker Price Performance

Shares of SYK opened at $345.64 on Thursday. The firm has a market cap of $132.27 billion, a PE ratio of 41.15, a price-to-earnings-growth ratio of 2.04 and a beta of 0.85. Stryker Corporation has a 52-week low of $328.23 and a 52-week high of $404.87. The business’s 50 day moving average price is $364.43 and its two-hundred day moving average price is $366.61. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.21 and a current ratio of 1.89.

Stryker (NYSE:SYK) last announced its quarterly earnings data on Thursday, January 29th. The medical technology company reported $4.47 EPS for the quarter, topping the consensus estimate of $4.40 by $0.07. The company had revenue of $7.17 billion during the quarter, compared to the consensus estimate of $7.12 billion. Stryker had a net margin of 12.92% and a return on equity of 24.41%. The company’s quarterly revenue was up 11.4% on a year-over-year basis. During the same quarter last year, the firm posted $4.01 EPS. On average, equities analysts anticipate that Stryker Corporation will post 13.47 EPS for the current year.

Stryker Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Thursday, April 30th. Shareholders of record on Tuesday, March 31st will be issued a $0.88 dividend. This represents a $3.52 dividend on an annualized basis and a yield of 1.0%. The ex-dividend date is Tuesday, March 31st. Stryker’s dividend payout ratio (DPR) is presently 41.90%.

Insiders Place Their Bets

In other Stryker news, Director Ronda E. Stryker sold 250,000 shares of Stryker stock in a transaction on Wednesday, February 4th. The shares were sold at an average price of $362.92, for a total value of $90,730,000.00. Following the completion of the sale, the director directly owned 2,457,331 shares of the company’s stock, valued at approximately $891,814,566.52. The trade was a 9.23% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Company insiders own 5.90% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages recently weighed in on SYK. Weiss Ratings restated a “hold (c+)” rating on shares of Stryker in a research report on Monday, December 22nd. Barclays reiterated an “overweight” rating and issued a $469.00 target price on shares of Stryker in a research report on Monday, February 2nd. Wall Street Zen upgraded Stryker from a “hold” rating to a “buy” rating in a report on Saturday, February 21st. TD Cowen downgraded Stryker from a “buy” rating to a “hold” rating and set a $387.00 price objective for the company. in a research note on Monday, January 26th. Finally, Jefferies Financial Group reiterated a “buy” rating and issued a $465.00 price objective on shares of Stryker in a report on Wednesday, March 4th. Fourteen analysts have rated the stock with a Buy rating and five have issued a Hold rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $427.50.

Stryker Company Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.